Ignite Creation Date:
2025-12-25 @ 1:46 AM
Ignite Modification Date:
2026-03-02 @ 7:44 AM
Study NCT ID:
NCT02397694
Status:
COMPLETED
Last Update Posted:
2020-04-07
First Post:
2015-03-20
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Sponsor:
Gilead Sciences
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-03-23
Start Date Type:
ACTUAL
Primary Completion Date:
2015-11-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-02-27
Completion Date Type:
ACTUAL
First Submit Date:
2015-03-20
First Submit QC Date:
None
Study First Post Date:
2015-03-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-02-27
Results First Submit QC Date:
None
Results First Post Date:
2018-03-27
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2016-08-24
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2020-03-25
Last Update Post Date:
2020-04-07
Last Update Post Date Type:
ACTUAL